Evidence map›Paper›PMID 31183384›Full record

Trial reportJournal of diabetes research2019

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.

Huiqin Li, Xiaohua Xu, Jie Wang, Xiaocen Kong, Maoyuan Chen, Ting Jing, Zhiying Zhang, Guoping Yin, Xiaomei Liu, Yun Hu and 3 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01644500. Cited by 15 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 5 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01644500 phase3completed

The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus

Ran2012Enrolled737Registered outcomes21Posted comparisons46ConditionsType 2 Diabetes MellitusArmsDulaglutide, Glimepiride, Placebo as Capsules, Placebo as SC Injection
Open the trial in the graph
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Significance of 8-iso-PGFAmerican heart journal plus : cardiology research and practice · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Huiqin LiDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0002-6319-1196
Xiaohua XuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Jie WangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Xiaocen KongDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0002-4254-7384
Maoyuan ChenDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ting JingDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Zhiying ZhangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Guoping YinDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Xiaomei LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Yun HuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0002-4477-3641
Lei YeNational Heart Research Institute Singapore, National Heart Centre Singapore, Singapore.ORCID 0000-0001-5039-6224
Xiaofei SuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0002-8263-7608
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.ORCID 0000-0001-9383-2559
Nanjing Medical University · CNNational Heart Centre Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS).

methodsA total of 23 patients with T2DM were randomly assigned into two groups for 26 weeks: the dulaglutide group (

resultsHbA1c of the dulaglutide group was reduced from 8.38 ± 0.93% to 6.68 ± 0.73% after the treatment (

conclusionOnce-weekly dulaglutide injection has the same effectiveness as daily glimepiride on lowering blood glucose and decreasing oxidation stress and inflammation and is more effective in controlling glucose fluctuation as compared with glimepiride. This trial is registered with ClinicalTrials.gov NCT01644500.

Indexed as

Drug Administration ScheduleBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2DinoprostFemaleFollow-Up StudiesGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsInflammationInterleukin-6MaleMiddle Aged8-epi-prostaglandin F2alphaBlood GlucoseDinoprostdulaglutideglimepirideGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsIL6 protein, humanImmunoglobulin Fc FragmentsInterleukin-6Recombinant Fusion ProteinsSulfonylurea CompoundsTumor Necrosis Factor-alpha

Identifiers

PMID31183384
PMCPMC6515022
OpenAlexW2943787579

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.